Harvard College

Washington Research Foundation

Other

University of Michigan

Kotoku Kurachi

Earl W Davie

Bert L Vallee

Savio L Woo

Chandra Thirumalachary

A novel, empirically derived composition of cytokines and myoblasts is described, that allows for the migration of myoblasts through connective barriers, along with methods employing the composition in the in vivo migration of myoblasts for therapeutic purposes and gene therapy, as well as methods for the identification of agents that are agonistic or antagonistic to myoblast migration in vitro or in vivo.

Method for enhancing myoblast migration and invasion in the context of gene therapy

DNA sequences to mammalian .alpha..sub.1 -antitrypsin are provided which can be used for expression of mammalian .alpha..sub.1 -antitrypsin. This work was supported in part by grants HL16919 and HL27509 from the National Institutes of Health.

DNA sequences expressing mammalian .alpha..sub.1 -antitrypsin

DNA sequences expressing mammalian .alpha..sub.1 antitrypsin

DNA sequences to mammalian .alpha..sub.1 -antitrypsin are provided which can be used for expression of mammalian .alpha..sub.1 -antitrypsin.

DNA sequences expressing mammalian alpha-1-antitrypsin

There is disclosed an isolated DNA sequence and the amino acid sequence for human factor IX. The isolated DNA sequence and its flanking sequences are useful for determining mutations, deletions or other modifications in genetic sequences expressing normal factor IX or modifications thereof.

DNA preparation of Christmas factor and use of DNA sequences

DNA sequences encoding a protein having angiogenic activity and mutated DNA sequences encoding a protein having decreased angiogenic activity are disclosed. Expression vectors containing these wild-type or mutated sequences are introduced into host cells and direct the production of wild-type or mutant angiogenic proteins. Proteins produced according to the invention are useful in the diagnosis of malignancies, for promoting wound healing, and for other diagnostic and therapeutic purposes. Mutant proteins produced according to the invention are useful therapeutic compositions as angiogensis inhibitors, which may retard tumor growth by inhibiting the development of a hemovascular network.

CDNA and genes for human angiogenin (angiogenesis factor) and methods of

DNA sequences encoding a protein having angiogenic activity are disclosed. Expression vectors containing these sequences are introduced into host cells and direct the production of the angiogenic protein. Proteins produced according to the invention are useful in the diagnosis of malignancies, for promoting wound healing, and for other diagnostic and therapeutic purposes.

CDNA and gene for human angiogenin (angiogenesis factor) and methods of

DNA sequences encoding a protein having angiogenic activity are disclosed. Expression vectors containing these sequences are introduced into host cells and direct the production of the angiogenic protein. Proteins produced according to the invention are useful in the diagnosis of malignancies, for promoting wound healing, and for other diagnositic and therapeutic purposes.

Growing community of inventors

Seattle, WA, United States of America

Kotoku Kurachi